12 Best Stocks Under $100 to Buy According to Hedge Funds

Page 3 of 11

9. Boston Scientific Corp. (NYSE:BSX)

Share Price as of April 22: $93.58

Number of Hedge Fund Holders: 96

Boston Scientific Corp. (NYSE:BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties. It operates in two segments: MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, urological conditions, and neurological movement disorders.

In Q4 2024, the company’s Electrophysiology (EP) sales surged by 172% year-over-year, while for the full year 2024, this segment was up 139%. This is attributed to the continued and rapid adoption of the company’s FerraPulse Pulsed Field Ablation (PFA) system, which has become a transformative technology in the Atrial Fibrillation (AFib) market. FerraPulse surpassed $1 billion in global revenue in 2024 and is treating more than 200,000 patients.

Boston Scientific Corp. (NYSE:BSX) is building clinical evidence for FerraPulse, which is highlighted by positive initial results from the ADDvantage AF trial (for evaluating the safety and effectiveness of the system). An updated label for persistent AF is expected in H2 2025, and enrollment for the Avantgarde trial (FerraPulse as a first-line treatment) is almost complete. Data for FerraPoint is expected in H1 2025, with potential FDA approval by year-end.

Janus Henderson Enterprise Fund stated the following regarding Boston Scientific Corporation (NYSE: BSX) in its Q2 2024 investor letter:

“Medical device company Boston Scientific Corporation (NYSE:BSX) was another contributor. The stock rose on excitement over the company’s U.S. launch of FARAPULSE, a state-of-the-art pulsed field ablation system that treats atrial fibrillation with less damage to surrounding tissues relative to previous therapies. Boston Scientific is currently the only provider of this technology, which taps into a large and growing addressable market. Even beyond our excitement around FARAPULSE, we continue to like Boston Scientific for its diversified product portfolio, which has provided many potential drivers of revenue growth.”

Page 3 of 11